Evidence for a link between IGF-I and cancer

Jenkins, Paul J.; Bustin, Stephen A.

doi:10.1530/eje.0.151s017

Cited by 79 publications

(52 citation statements)

References 48 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…More probable explanation is that elevated levels of this peptide reflect increased activity of the growth hormone-IGF-1 axis, which may contribute to the development of prolactinoma through its influence on the regulation of normal cell proliferation, differentiation and apoptosis [20]. In line with our hypothesis, we observed the presence of correlations between baseline IGF-1 levels and baseline levels of triglycerides, HDL cholesterol, 2-hr post-challenge plasma glucose, HOMA-IR, FFA, uric acid, hsCRP and homocysteine.…”

Section: Discussionmentioning

confidence: 99%

Different Effects of Cabergoline and Bromocriptine on Metabolic and Cardiovascular Risk Factors in Patients with Elevated Prolactin Levels

Krysiak

2014

Basic Clin Pharma Tox

View full text Add to dashboard Cite

Hyperprolactinaemia is suggested to be associated with metabolic and hormonal complications. No previous study has compared the effect of different dopamine agonists on plasma lipids, carbohydrate metabolism markers and cardiovascular risk factors in patients with elevated prolactin levels. The study included eight bromocriptine-resistant women with prolactinoma (group 1) and twelve matched women with hyperprolactinaemia unrelated to prolactinoma (group 2). Group 1 was then treated with cabergoline, while group 2 with bromocriptine. Plasma lipids, glucose homeostasis markers and plasma levels of prolactin, insulin-like growth factor-1 (IGF-1) and cardiovascular risk factors were assessed before and after 6 months of therapy. Both treatments normalized plasma prolactin levels. Cabergoline reduced triglycerides, 2-hr post-challenge plasma glucose, the homeostatic model assessment of insulin resistance (HOMA-IR), and circulating levels of IGF-1, free fatty acids (FFA), uric acid, highsensitivity C-reactive protein (hsCRP), homocysteine and fibrinogen, as well as increased HDL cholesterol and 25-hydroxyvitamin D. With the exception of a reduction in HOMA-IR, bromocriptine treatment produced no significant effect on the investigated biomarkers. Cabergoline was superior to bromocriptine in affecting 2-hr post-challenge plasma glucose levels, HOMA-IR, as well as circulating levels of IGF-1, FFA, uric acid, hsCRP, homocysteine, fibrinogen and 25-hydroxyvitamin D. Our results may suggest that cabergoline is superior to bromocriptine when it comes to affecting atherogenic dyslipidaemia, insulin sensitivity and circulating levels of cardiovascular risk factors in hyperprolactinaemic patients. These findings seem to support previous observations that cabergoline may be a better treatment for patients with elevated prolactin levels than bromocriptine.Apart from oligomenorrhea, infertility, galactorrhoea, loss of libido and sexual dysfunction, long-term prolactin excess is often complicated by impaired glucose tolerance, hyperinsulinaemia, insulin resistance, atherogenic dyslipidaemia, subclinical atherosclerosis, endothelial dysfunction and weight gain [1][2][3][4][5][6][7][8]. These abnormalities may be alleviated or reversed by dopamine agonists, being the drugs of choice in the treatment of prolactin-secreting tumours and elevated prolactin levels secondary to other disorders [9]. Dopamine agonist-induced normalization of elevated prolactin levels reduced body-weight [7,10] and improved insulin receptor action [4]. The effect of cabergoline on waist circumference, plasma lipids, glycated haemoglobin, insulin and the homeostatic model assessment of insulin resistance (HOMA-IR), despite dose dependency, was observed regardless of the degree of reduction in prolactin levels [11]. Cabergoline administered to patients with newly diagnosed prolactinoma exerted systemic anti-inflammatory effects, as well as reduced carotid intima-media thickness, and these effects were independent from a decrease in prolactin levels, b...

show abstract

Section: Discussionmentioning

confidence: 99%

Different Effects of Cabergoline and Bromocriptine on Metabolic and Cardiovascular Risk Factors in Patients with Elevated Prolactin Levels

Krysiak

2014

Basic Clin Pharma Tox

View full text Add to dashboard Cite

show abstract

“…Besides cell growth-promoting activity, IGFs are also potent survival factors that may prevent cellular apoptosis of tumor cells, blood vessel endothelial cells, and lymphatic endothelial cells (29)(30)(31). Thus, development of IGF antagonists may be an important approach for the treatment of cancer and metastasis.…”

Section: Discussionmentioning

confidence: 99%

“…The IGFBPs may modulate the biological activity of IGFs (28). There is increasing evidence that IGF-1 might contribute to cancer development by regulating cell proliferation, differentiation, and cell death (29)(30)(31). Both IGF-1 and IGF-2 induce angiogenesis in several in vitro and in vivo systems (32)(33)(34)(35).…”

mentioning

confidence: 99%

Insulin-like growth factors 1 and 2 induce lymphangiogenesis in vivo

Björndahl

Cao

Nissen

et al. 2005

Proc. Natl. Acad. Sci. U.S.A.

221

163

View full text Add to dashboard Cite

Lymphangiogenesis is an important process that contributes to the spread of cancer. Here we show that insulin-like growth factors 1 (IGF-1) and 2 (IGF-2) induce lymphangiogenesis in vivo. In a mouse cornea assay, IGF-1 and IGF-2 induce lymphangiogenesis as detected with LYVE-1, a specific marker for lymphatic endothelium. angiogenesis ͉ insulin-like ͉ growth factor family ͉ vascularization ͉ tumor growth ͉ metastasis

show abstract

“…Height may reflect hereditary factors, nutrition in the remote past or may be a marker for exposure levels to growth factors, including IGF-1, which is mitogenic and antiapoptotic. IGF-1 has been suggested to play a role in several of these cancers, [28][29][30] including bladder cancer. 31,32 In light of this mechanism, height, as a marker of high IGF-1 levels, would be expected to increase the risk of bladder cancer.…”

Section: Discussionmentioning

confidence: 99%

Prospective study of body mass index, height, physical activity and incidence of bladder cancer in US men and women

Holick

Giovannucci

Stampfer

et al. 2006

Intl Journal of Cancer

View full text Add to dashboard Cite

We evaluated prospectively the association between body mass index (BMI), height, recreational physical activity and the risk of bladder cancer among US adults. Data were used from 2 ongoing cohorts, the Health Professionals Follow-up Study and the Nurses' Health Study, with 3,542,012 years of follow-up and 866 incident bladder cancer cases (men 5 507; women 5 359) for the anthropometric analysis and 1,890,476 years of follow-up and 706 incident bladder cancer cases (men 5 502; women 5 204) for the physical activity analysis. Cox proportional hazard models were used to estimate incidence rate ratios (RR) and 95% confidence intervals (CI) between BMI, height, physical activity and bladder cancer risk adjusting for age, pack-years of cigarette smoking and current smoking. Estimates from each cohort were pooled using a random-effects model. We observed no association between baseline BMI and bladder cancer risk, even when we compared a BMI of 30 kg/m 2 to a BMI of 18-22.9 Key words: body mass index; physical activity; bladder cancer; prospective studies; epidemiology An estimated 65% of adults in the US are currently overweight [a body mass index (BMI) between 25.0 and 29.9 kg/m 2 ] or obese (BMI of 30.0 kg/m 2 or greater). 1 Overweight and obesity are associated with heart disease, stroke, diabetes, altered mental status, respiratory problems and various digestive and musculoskeletal disorders. 2 There is growing evidence that obesity is associated with overall cancer and several site-specific cancer sites including breast (in postmenopausal women), colon, esophagus, kidney and endometrium 2 ; however, the relation between obesity and the risk of bladder cancer remains speculative.Data from studies examining weight or BMI, 3-13 height, 14,15 physical activity 8,9,16 and the subsequent risk of bladder cancer are inconsistent. The lack of consistency may be attributable to uncontrolled or residual confounding by cigarette smoking, 3,[6][7][8]14 potential recall or selection bias in case-control studies, 4,10,12,14 measurement error in the physical activity assessment 7,9 or small numbers of bladder cancer cases. 3,6,8,9,11,16 Furthermore, some studies that have investigated the association of these factors with bladder cancer risk have focused on men only 7,12,16 or have included few women. 3,8,11,13,14 Given the limitations of previous studies evaluating the role of anthropometric characteristics, physical activity and the risk of bladder cancer, including limited data on women, we conducted a prospective investigation in 2 large cohort studies of men and women. Material and methods Study populationsThe Nurses' Health Study (NHS) was initiated in 1976 when 121,700 registered US female nurses, aged 30-55 years, returned a mailed questionnaire that assessed information on lifestyle factors, medical and smoking histories. Similarly, the Health Professionals Follow-Up Study (HPFS) is a cohort of 51,529 US male dentists, optometrists, osteopaths, podiatrists, pharmacists and veterinarians who were 40-75 years of age a...

show abstract

Evidence for a link between IGF-I and cancer

Cited by 79 publications

References 48 publications

Different Effects of Cabergoline and Bromocriptine on Metabolic and Cardiovascular Risk Factors in Patients with Elevated Prolactin Levels

Different Effects of Cabergoline and Bromocriptine on Metabolic and Cardiovascular Risk Factors in Patients with Elevated Prolactin Levels

Insulin-like growth factors 1 and 2 induce lymphangiogenesis in vivo

Prospective study of body mass index, height, physical activity and incidence of bladder cancer in US men and women

Contact Info

Product

Resources

About